1648-P: Real-World Experiences with Teplizumab: U.S. HCP Perspectives on Infusion Practices
Diabetes · 05.06.2026 · 75 (Supplement_1)
DOI: 10.2337/db26-1648-p ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, erschienen am 05.06.2026. Verfasst von KOREY HOOD und 6 weiteren Autor:innen.
Abstract (Originalsprache)
Introduction and Objective: Teplizumab (TPZ) is the first disease-modifying therapy approved to delay progression from stage 2 (s2) to 3 T1D. Yet, little is known about TPZ use in real world (RW) practice.
Methods
This mixed methods survey invited adult and pediatric HCPs with ≥1 US TPZ patients to complete a 1-hour, semi-structured interview that included elements of validated scales (Oct-Nov 2025). Interviews queried HCPs on TPZ initiation and treatment, care coordination and operational logistics, and adverse event management. Scales scores were calculated and interviews analyzed with this preliminary thematic analysis.
Results
Qualitative findings from 39 HCPs identified 5 main themes: 1) HCPs want to offer TPZ to give patients more treatment options, 2) TPZ includes a time-consuming insurance approval process with varying lab requirements, 3) current s2 eligibility limits access; there is a need for earlier and expanded T1D screening, 4) infusion location and capability was logistically difficult, yet HCPs consistently emphasized TPZ’s evidence of beneficial, clinically meaningful outcomes, 5) HCPs thought the clinical value of TPZ outweighed challenges and expressed optimism about expanding future use. Table 1 contains survey results.
Conclusion
This study provides insights into RW TPZ infusion experiences, highlighting enthusiasm for TPZ, implementation challenges, adoption facilitators and barriers, and promising implementation practices. Disclosure K. Hood: Consultant; Current; Sanofi, MannKind Corporation, Insulet Corporation. S. Mehta: None. S.R. Bialo: Employee; Current; Sanofi. Employee; Ended; Provention Bio, Inc. T.A. Dex: Stock/Shareholder; Current; Sanofi, Pfizer Inc., Teva Pharmaceutical Industries Ltd. M. Graf: None. R. Wilson: Other - Rozanne Wilson is employed by Precision AQ, a consulting firm that was contracted by Sanofi to conduct research services related to the project. She did not receive direct compensation from Sanofi outside of her regular salary.; Current; Sanofi. N. Bleibdrey: Employee; Current; Sanofi. Stock/Shareholder; Current; Sanofi-Aventis U.S.
Zitieren
APA
HOOD, K., MEHTA, S., BIALO, S. R., DEX, T. A., GRAF, M., WILSON, R., & BLEIBDREY, N. (2026). 1648-P: Real-World Experiences with Teplizumab: U.S. HCP Perspectives on Infusion Practices. Diabetes, 75(Supplement_1). https://doi.org/10.2337/db26-1648-p
Vancouver
HOOD K, MEHTA S, BIALO SR, DEX TA, GRAF M, WILSON R, et al. 1648-P: Real-World Experiences with Teplizumab: U.S. HCP Perspectives on Infusion Practices. Diabetes. 2026;75(Supplement_1). doi:10.2337/db26-1648-p
BibTeX
@article{HOOD2026,
author = {HOOD, KOREY and MEHTA, SHILPA and BIALO, SHARA R. and DEX, TERRY A. and GRAF, MARLON and WILSON, ROZANNE and BLEIBDREY, NATALY},
title = {1648-P: Real-World Experiences with Teplizumab: U.S. HCP Perspectives on Infusion Practices},
journal = {Diabetes},
year = {2026},
volume = {75},
number = {Supplement_1},
doi = {10.2337/db26-1648-p}
}
EUVIMED